| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | NSC23766 | CTRPv2 | pan-cancer | AAC | 0.046 | 0.2 |
| mRNA | GDC-0879 | CTRPv2 | pan-cancer | AAC | -0.046 | 0.2 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.044 | 0.2 |
| mRNA | YM-155 | CTRPv2 | pan-cancer | AAC | 0.049 | 0.2 |
| mRNA | CD-1530 | CTRPv2 | pan-cancer | AAC | 0.049 | 0.2 |
| mRNA | BRD-K51831558 | CTRPv2 | pan-cancer | AAC | 0.069 | 0.2 |
| mRNA | BRD-K33514849 | CTRPv2 | pan-cancer | AAC | 0.16 | 0.2 |
| mRNA | silmitasertib | CTRPv2 | pan-cancer | AAC | 0.05 | 0.2 |
| mRNA | lenvatinib | CTRPv2 | pan-cancer | AAC | 0.047 | 0.2 |
| mRNA | AZ-3146 | CTRPv2 | pan-cancer | AAC | -0.045 | 0.2 |